April 20, 2026
2 min read
Key takeaways:
- Revenio’s goal of the acquisition is to become “a leading turnkey solutions provider” in eye care.
- The companies said their product portfolios complement each other and have little overlap.
Revenio Group, the parent company behind the iCare product line, has agreed to acquire Visionix, maker of Optovue OCT systems and other tools for optometry practices, according to a press release.
“This is a landmark moment for Visionix and for the eye care industry in the United States,” Marc Abitbol, CEO of Visionix, told Healio. “By joining forces with Revenio Group, we gain access to a broader portfolio of world-class diagnostic technologies, greater scale and the resources needed to better serve our customers — from independent optometrists and optical retail chains to hospital-based ophthalmology practices. The combination accelerates our ability to deliver the comprehensive, connected care solutions that eye care professionals across the country are increasingly demanding.”
In an announcement from Visionix, the companies said the deal is intended to foster “a broader and more integrated eye care offering” and highlighted the lack of overlap between their products.
Revenio is the parent company of iCare, which makes handheld rebound tonometers and tools for retinal imaging and perimetry. In addition to the Optovue family of OCT imaging devices, Visionix makes various devices for clinical screening, refractive assessment, fundus photography, lens finishing and more.
“Together with Visionix, we position ourselves as a leading turnkey solutions provider for a wide range of eye care needs,” Jouni Toijala, CEO of Revenio, said in the release. “From Revenio’s point of view, we accelerate our entry into the OCT segment, representing an important step in fulfilling our goal to improve the quality of ophthalmic diagnostics through innovative products and software solutions.”
In the release, Abitbol said the deal is “an opportunity to take Visionix to another level with a partner whose technology, product portfolio, leadership and values are deeply complementary to our own.”
“During the process, I was impressed by the natural adhesion of both teams to this vision, which gives me great confidence in the human and entrepreneurial potential of the combined group,” he said.
For more information:
Visionix can be reached at marketing_us@visionix.com.
Sources/Disclosures
Source:
Press Release
References:
Disclosures:
Abitbol reports being CEO of Visionix.
Ask a clinical question and tap into Healio AI’s knowledge base.
- PubMed, enrolling/recruiting trials, guidelines
- Clinical Guidance, Healio CME, FDA news
- Healio’s exclusive daily news coverage of clinical data
<
Leave a Reply